Get started
ADVERUM BIOTECHNOLOGIES INC USD0.0001ADVERUM BIOTECHNOLOGIES INC USD0.0001ADVERUM BIOTECHNOLOGIES INC USD0.0001

ADVERUM BIOTECHNOLOGIES INC USD0.0001

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

0HA3 trade ideas

ADVM - Biotech Long ShotBiotechs are still beaten up, especially the gene therapy disrupter stocks, so continuing to buy a little bit here and a little bit here of some of these stocks. These are lottery stocks, they have few if any marketable products, but the idea is if they do come out with a block buster, well winner winner chicken dinner!!! Adverum is into ocular gene therapy with several therapies in the pipeline with one to be late-stage clinical study. Reason for the buy? Well a nice insider buy trade of $2.5 million in July which can often be a sign that something is in the making, or at least they have a lot of faith in the company moving forward. Probably buy 100 shares here, that is a small under $700 position so if it goes to zero I am not hurting, but if it becomes a 10 or better bagger that is a nice hit. I mean various investors had the company above $200 for a while, so it is not unreasonable to get that type of move. However the chances of that are low which is why we keep our risk low. Anyways, good luck and I will touch base soon.
NASDAQ:ADVMLong
by goldbug1
Adverum Biotechnologies, Inc.On the above bi-Weekly chart price action has corrected over 90% since June 2020. A number of reasons now exist to be bullish , including: 1) A strong buy signal prints (not shown). 2) Regular bullish divergence . Multiple oscillators printing divergence. 3) Price action confirms support on past resistance. 4) Falling wedge breakout + backtest. Is it possible price action falls further? Sure. Is it probable? No. Ww Type: trade Risk: <=6% of portfolio Timeframe: Don’t know. Return: Don’t know Stop loss: <= 50 cents
NASDAQ:ADVMLong
by without_worries
7
ADVM Technical Analysis 🧙Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durability with treatment response, reduce the treatment burden of frequent anti-vascular endothelial growth factor (anti-VEGF) injections, and improve real-world vision outcomes for patients.
NASDAQ:ADVMLong
by unfair_advantage
Adverum Biotechnologies Inc 🧙Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durability with treatment response, reduce the treatment burden of frequent anti-vascular endothelial growth factor (anti-VEGF) injections, and improve real-world vision outcomes for patients. If you want not to miss ideas like this one,🎯 subscribe and press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:ADVMLong
by unfair_advantage
ADVM Technical Analysis 🧙Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durability with treatment response, reduce the treatment burden of frequent anti-vascular endothelial growth factor (anti-VEGF) injections, and improve real-world vision outcomes for patients. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:ADVMLong
by unfair_advantage
ADVM Technical Analysis 🧙Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durability with treatment response, reduce the treatment burden of frequent anti-vascular endothelial growth factor (anti-VEGF) injections, and improve real-world vision outcomes for patients. If you want more trading ideas like this one ,🎯 press a thumb up! 👍 Have a question? Don't be shy to ask! 🤓 Interested to study how to analyze charts, follow me!
NASDAQ:ADVMLong
by unfair_advantage
ADVM Showing Strong Momentum Price recently broke out of 10 month triangle formation. I am looking at price support atop breakout level @16.25 and the accelerating divergence of the 50 MA and 200 MA without the two ever crossing. On Balance Volume appears to be primed for a move higher without pulling back to 100 EMA and the MACD appears to me to be primed for a reacceleration as well, which conveys continuation higher will come with high momentum and a large and fast move could be upon us. Holding the breakout level at 16.25 is critical to bull thesis, prior gap fill to $28.50 is certainly possible, $26 seems reasonable. I am looking to enter full position at 20.50, which was the close of the long upper wick candle May 6.
NASDAQ:ADVMLong
by ETrades1